Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center

BACKGROUND: Poor-risk advanced Renal cell carcinoma (RCC) are an under-evaluated and difficult to treat subset of patients with poor prognosis. While Temsirolimus is the approved first line therapy for this category, Tyrosine kinase inhibitors (TKIs) are also commonly uses as initial treatment. We p...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Indian J Med Paediatr Oncol
Huvudupphovsmän: Ramaswamy, Anant, Joshi, Amit, Noronha, Vanita, Patil, Vijay, Sahu, Arvind, Manickam, Deepan R, Kothari, Rushabh, Sable, Nilesh, Agrawal, Archi, Menon, Santosh, Prabhash, Kumar
Materialtyp: Artigo
Språk:Inglês
Publicerad: Medknow Publications & Media Pvt Ltd 2017
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5686973/
https://ncbi.nlm.nih.gov/pubmed/29200680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijmpo.ijmpo_154_16
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk